182 related articles for article (PubMed ID: 134476)
1. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Tubercle; 1976 Jun; 57(2):81-95. PubMed ID: 134476
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
3. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Zierski M; Bek E
Tubercle; 1980 Mar; 61(1):41-9. PubMed ID: 6989067
[TBL] [Abstract][Full Text] [Related]
4. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
Tubercle; 1975 Jun; 56(2):81-96. PubMed ID: 1103400
[TBL] [Abstract][Full Text] [Related]
5. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Girling DJ
Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
[TBL] [Abstract][Full Text] [Related]
6. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423
[TBL] [Abstract][Full Text] [Related]
8. Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore.
Jenner PJ; Ellard GA; Allan WG; Singh D; Girling DJ; Nunn AJ
Tubercle; 1981 Sep; 62(3):175-9. PubMed ID: 7314249
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis; 1979 Apr; 119(4):579-85. PubMed ID: 375787
[TBL] [Abstract][Full Text] [Related]
10. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
Am Rev Respir Dis; 1977 May; 115(5):727-35. PubMed ID: 857713
[TBL] [Abstract][Full Text] [Related]
11. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
12. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.
Aquinas M; Allan WG; Horsfall PA; Jenkins PK; Hung-Yan W; Girling D; Tall R; Fox W
Br Med J; 1972 Mar; 1(5803):765-71. PubMed ID: 4259217
[TBL] [Abstract][Full Text] [Related]
14. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
15. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
[TBL] [Abstract][Full Text] [Related]
16. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
[TBL] [Abstract][Full Text] [Related]
17. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy.
Rac VV; Gupta EV; Thomas IM
Mutat Res; 1991 Jan; 259(1):13-9. PubMed ID: 1988820
[TBL] [Abstract][Full Text] [Related]
19. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.
Tubercle; 1986 Mar; 67(1):5-15. PubMed ID: 3521015
[TBL] [Abstract][Full Text] [Related]
20. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
Hong Kong Chest Service/British Medical Research Council
Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
